Notably, a clinical study demonstrated that T2DM patients receiving insulin therapy experienced significantly higher rates of pancreatitis compared to those treated with GLP-1RAs, and notably, no pancreatitis cases have been reported in clinical trials of the novel GLP-1RA Cotadutide, indicating that a comprehensive risk assessment of GLP-1RAs for pancreatic cancer remains premature pending additional data on these novel medications [8]. Here, INS is linked to pancreatitis.